Figure 1

Study flow. Responders were defined as patients who received a minimum dosage of milnacipran 100 mg/day and achieved ≥50% pain improvement after long-term treatment. ^aPatients not meeting responder criteria were analyzed separately, but the results for these patients are not presented in the current report. "Nonresponder" does not necessarily imply no improvement. ^bWorsening of fibromyalgia requiring alternative treatment, which was one of the loss of therapeutic response (LTR) criteria used for the primary efficacy analysis and for sensitivity analysis III. ^cPatients reaching the final study visit. ^dOne patient who did not receive at least one dose of the study drug was excluded from safety and efficacy analyses. OL = open-label.